Compare Inovio Pharmaceuticals Inc (INO) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Xpeng Inc - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Xpeng Inc - ADR is far larger — about 81.6× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Xpeng Inc - ADR for 80 Days on average.
| INO | XPEV | |
|---|---|---|
Market Cap | $112.19M | $9.16B |
Volume | 3,201,278 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $28.07 |
52-Week Low | $0.66 | $9.25 |
Typical Hold Time | 43 Days | 80 Days |
Enterprise Value | $83.51M | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
XPeng (XPEV) trades at $9.92, up 3.55% today, but remains in a bearish technical trend. The company shows mixed fundamentals with strong revenue growth to $76.72B in 2025 but persistent net losses. Recent Q2 2026 earnings missed expectations, though vehicle deliveries surged 65% quarter-over-quarter. Analyst consensus remains bullish with a $17.55 price target, representing 77% upside potential from current levels.
XPeng presents a high-risk, high-reward opportunity with significant growth potential in EVs and robotics, but profitability challenges and competitive pressures create substantial risk. The stock's current valuation at 0.81 P/S appears attractive if the company can achieve sustainable profitability, but investors face execution risk amid China's competitive EV market and global expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
